Genetic Counselling: the biomedical bridge between molecular diagnosis and precision treatment
Tóm tắt
Since the development of genomics, we are able to understand backgrounds of differential pathogenicity of metabolic disorders. Molecular diagnosis has become inevitable for metabolic, neuro-psychiatric and genetic disorders due to highly overlapping pathophysiological symptoms. The present lacuna between clinical prescription and molecular diagnosis is very prominent and can only be filled up through experts who can function as the bridge in between. In this present review, the authors tried to focus on the role of genetic counselors in disease diagnosis as well as scopes of disease biology in utilizing the expertise of genetic professional for precision treatments of patients. We summarized four major disease areas, Cancer management, Obstetrics and Gynecology, Newborn Screening and Rare Genetic Disorders, where molecular diagnosis and genetic counseling can highly support the clinicians in precision treatment of the patients. Idiopathic reproductive failures, clinically overlapping neuro-psychiatric disorders, chromosomal aberrations in progressing tumors, rare genetic disorders all the disease areas can find out fruitful intervention when enlightened with molecular diagnosis and genetic counseling. Though, genetic counseling is commonly practiced in intervening reproductive problems, newborn screening and cancer, still the scope of genetic counselor in successfully intervening multiple rare genetic diseases as well as common hereditary life style disorders, remain extremely high. The liaison between clinicians and geneticists, specifically clinical prescription and genetic diagnosis is one of the key demands of present age, which can be successfully fulfilled by the genetic counselors. For these reasons, genetic counseling is predicted as the biomedical career of future due to being in the vital position for successful implementation of precision medicine.
Tài liệu tham khảo
Patch C, Middleton A (2018) Genetic Counselling in the Era of Genomic Medicine. Br Med Bull. https://doi.org/10.1093/bmb/ldy008
Resta R, Biesecker BB, Bennett RL, Blum S, Hahn SE, Strecker MN, Williams JL (2006) A New Definition of Genetic Counseling: National Society of Genetic Counselors’ Task Force Report. J Genet Counsel. https://doi.org/10.1007/s10897-005-9014
Rahner N, Steinke V (2008) Hereditary cancer syndromes. Dtsch Arztebl Int. https://doi.org/10.3238/arztebl.2008.0706
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: Cancer J Clin. 2021. https://doi.org/10.3322/caac.21660.
Baird PA, Anderson TW, Newcombe HB, Lowry RB (1988) Genetic disorders in children and young adults: a population study. Am J Hum Genet 42:677–693
Hanif MI, Khan A, Arif A, Shoeb E (2019) Cytogenetic investigation of couples with recurrent spontaneous miscarriages. Pak J Med Sci. https://doi.org/10.12669/pjms.35.5.678
Kalotra V, Lall M, Saviour P, Verma IC, Kaur A (2017) Prevalence of cytogenetic anomalies in couples with recurrent miscarriages: a case-control study. J Hum Reprod Sci. https://doi.org/10.4103/jhrs.JHRS_68_17
Kar B, Catherine BL (2017) Genetic factors associated with recurrent pregnancy loss. Obstet Gynecol Int J. https://doi.org/10.15406/ogij.2017.07.00272
Dutta UR, Rajitha P, Pidugu VK, Dalal AB (2011) Cytogenetic abnormalities in 1162 couples with recurrent miscarriages in southern region of India: report and review. J Assist Reprod Genet. https://doi.org/10.1007/s10815-010-9492-6
Dailey T, Dale B, Cohen J, Munné S (1996) Association between nondisjunction and maternal age in meiosis-II human oocytes. Am J Hum Genet 59(1):176–184
Pellestor F, Anahory T, Hamamah S (2005) Effect of maternal age on the frequency of cytogenetic abnormalities in human oocytes. Cytogenet Genome Res. https://doi.org/10.1159/000086891
Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJ, Adams J (2015) Semin Perinatol 39(3):171–187. https://doi.org/10.1053/j.semperi.2015.03.002
King JR, Hammarström L (2018) Newborn screening for primary immunodeficiency diseases: history, current and future practice. J Clin Immunol 38(1):56–66. https://doi.org/10.1007/s10875-017-0455-x
Martínez-Morillo E, Prieto García B, Álvarez Menéndez FV (2016) Challenges for worldwide harmonization of newborn screening programs. Clin Chem 62(5):689–698. https://doi.org/10.1373/clinchem.2015.240903
Genetic And Rare Disease Information Center, under NCATS, NIH, US Department of Health and Human Services. https://www.rarediseases.info.nih.gov.
Hamad E, Feldman AM (2010) Pharmacogenetics in heart failure: how it will shape the future. Heart Fail Clin. https://doi.org/10.1016/j.hfc.2009.08.013
Luisada L (1941) Favism: singular disease affecting chiefly red blood cells. Medicine 20:229–250
GaSG S (1957) Sensitivity to broad beans. Lancet. https://doi.org/10.1016/S0140-6736(57)90757-2
Chowdhury A, Santra A, Bhattacharjee K, Ghatak S, Saha DR, Dhali GK (2006) Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol 45(1):117–126. https://doi.org/10.1016/j.jhep.2006.01.027
Dompreh A, Tang X, Zhou J, Yang H, Topletz A, Adu Ahwireng E, Antwi S, Enimil A, Langaee T, Peloquin CA, Court MH, Kwara A (2018) Effect of genetic variation of NAT2 on isoniazid and SLCO1B1 and CES2 on rifampin pharmacokinetics in ghanaian children with tuberculosis. Antimicrob Agents Chemother 62(3):e02099-e2117. https://doi.org/10.1128/AAC.02099-17
Yuliwulandari R, Susilowati RW, Wicaksono BD, Viyati K, Prayuni K, Razari I, Kristin E, Syafrizal, Subagyo, Diana ES, Setiawati S, Ariyani A, Mahasirimongkol S, Yanai H, Mushiroda T, and Tokunaga K. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. J Hum Genet. 2016;61:533–537. https://doi.org/10.1038/jhg.2016.10